Bulletin
Investor Alert

New York Markets Close in:

Topics

Pfizer Inc.

/marketstate/country/us

Countdown to close

3:39 p.m.

PFE
Pfizer Inc.
/zigman2/quotes/202877789/composite

$

39.51

Change

+0.20 +0.52%

Volume

Volume 13.18m

Real time quotes

/zigman2/quotes/202877789/composite

Previous close

$ 39.30

$ 39.51

Change

+0.20 +0.52%

Day low

Day high

$39.07

$39.56

Open

52 week low

52 week high

$29.94

$43.08

Open

Video

States Pile On Covid-19 Vaccine Incentives. Will They Pay Off?

  • States Pile On Covid-19 Vaccine Incentives. Will They Pay Off? States Pile On Covid-19 Vaccine Incentives. Will They Pay Off? 6:43
    Vaccine Side Effects: What to Expect After Your Covid-19 Shot Vaccine Side Effects: What to Expect After Your Covid-19 Shot 5:01
    Stock Summer Swoon Coming? Stock Summer Swoon Coming? 9:15
    China Considers Boosting Covid-19 Vaccine Efficacy. Mixing Is One Way. China Considers Boosting Covid-19 Vaccine Efficacy. Mixing Is One Way. 4:19
9:42 a.m. Today - By Ciara Linnane
CureVac says its COVID vaccine was poor match against 29 COVID variants, as global case tally tops 177 millionThe global tally of confirmed cases of COVID-19 climbed above 177 million on Thursday, a day after disappointing news from CureVac with the German company saying its vaccine was only 47% effective in a late-stage clinical trial.
8:06 a.m. Today - By Jack Denton
Looking for hedges against inflation? Try Apple, Nike, Verizon and stocks with this in common, strategists sayStocks are set for a poor performance on Thursday, as markets absorb the Federal Reserve’s indication that interest rate increases are coming sooner than expected, while the central bank remains alert to inflation risks.
3:25 a.m. Today - By Claudia Assis
CureVac's COVID vaccine candidate 47% effective, stock tanks Shares of Curevac NV plunged more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
2:44 a.m. Today - By Barbara Kollmeyer
CureVac tumbles 41% in premarket on COVID-19 vaccine disappointmentShares of CureVac fell 42% in premarket trading on Thurdsay, a day after its COVID-19 vaccine was 47% effective in preventing the disease. CureVac's study, conducted in 10 countries and involving 40,000 people, showed the vaccine's struggle against a "fast changing environment" of at least 29 COVID-19 variants, with the original coronavirus strain "almost completely absent." Efficacy rates were at 90% for competing candidates of CureVac's messenger RNA-based vacine from Pfizer and BioNTech and Moderna . Millions have already been vaccinated with those.
2:25 a.m. Today - By Ciara Linnane
Coronavirus tally: Global cases of COVID-19 top 177 million and CureVac vaccine is just 47% effectiveThe global tally for the coronavirus-borne illness headed above 177 million on Thursday, , while deaths climbed above 3.8 million. The U.S. continues to lead the world in total cases at 33.49 million, while deaths total 600,653. The number of fully vaccinated Americans rose to 146.5 million, or 44% of the total population, according to , with the number of U.S. adults receiving at least one dose increasing to 64.7%. There was disappointing news on the CureVac vaccine when the company said well below the more than 90% efficacy of the vaccines developed by Pfizer Inc. and BioNTech SE and Moderna Inc. , which also use mRNA technology. CureVac said that its "pivotal" study, conducted in 10 countries and involving about 40,000 people, showed the vaccine candidate's being a poor match against a "fast changing environment" of at least 29 COVID-19 variants, with the original coronavirus strain "almost completely absent." The news sent its stock down sharply premarket. On a global basis, India is second in total cases at 29.7 million and third by fatalities at 381,903, although those numbers are expected to be undercounted given a shortage of tests. Brazil has the third-highest caseload at 17.6 million, according to JHU data, and is second in deaths at 493,693. Mexico has fourth-highest death toll at 230,624 and 2.5 million cases. The U.K. has 128,190 fatalities and 4.6 million cases, the highest number of deaths in Europe and fifth-highest in the world.
3:35 p.m. June 16, 2021 - By Ciara Linnane
CDC aligns with WHO on delta COVID variant; experts warn of higher risks of infection and serious illnessThe Centers for Disease Control and Prevention has reclassified the Delta variant of COVID-19 as one "of concern," underscoring how much more prevalent the B.1.617.2 variant first identified in India is becoming in the U.S.
1:15 p.m. June 16, 2021 - By MarketWatch Automation
1:09 p.m. June 16, 2021 - By MarketWatch Automation
1:00 p.m. June 16, 2021 - By MarketWatch Automation
12:46 p.m. June 16, 2021 - By MarketWatch Automation
12:41 p.m. June 16, 2021 - By MarketWatch Automation
12:39 p.m. June 16, 2021 - By MarketWatch Automation
12:36 p.m. June 16, 2021 - By MarketWatch Automation
12:33 p.m. June 16, 2021 - By MarketWatch Automation
12:32 p.m. June 16, 2021 - By MarketWatch Automation
10:00 p.m. June 15, 2021 - Barrons.com
Join Barron's Investing in Tech Conference: Watch Interviews With the CEOs of BioNTech, IAC, and C3.ai. Palantir CEO Alex Karp and BioNTech CEO Ugur Sahin are among executives who will be interviewed live at the Barron's event Wednesday.
2:46 p.m. June 15, 2021 - By Ciara Linnane
Fear grows that delta variant will become dominant COVID strain worldwide as WHO says it's now in 74 countriesThe Delta variant of COVID-19 has now been detected in 74 countries, prompting fears it will become the dominant strain around the world, as it continues to spread rapidly including in Southern U.S. states that have lagged on vaccination.
1:15 p.m. June 15, 2021 - By MarketWatch Automation
1:09 p.m. June 15, 2021 - By MarketWatch Automation
1:00 p.m. June 15, 2021 - By MarketWatch Automation
12:46 p.m. June 15, 2021 - By MarketWatch Automation
12:41 p.m. June 15, 2021 - By MarketWatch Automation
12:40 p.m. June 15, 2021 - By MarketWatch Automation
12:36 p.m. June 15, 2021 - By MarketWatch Automation
12:33 p.m. June 15, 2021 - By MarketWatch Automation
12:32 p.m. June 15, 2021 - By MarketWatch Automation
8:38 a.m. June 15, 2021 - By MarketWatch
New York lifts most remaining COVID restrictions as 70% of adults have received at least one vaccine doseMost remaining COVID restrictions in New York will be lifted as 70% of state residents aged 18 years-and-older have received at least a first dose of a coronavirus vaccine, Gov. Andrew Cuomo announced Tuesday. The lifting of state-mandated restrictions is effective immediately. Mask requirements set by the Centers for Disease Control and Prevention for pre-K schools, public transit and healthcare settings remain intact. New York has fully vaccinated 45.7% of its population so far, That means that share of the population has received two shots of the two-dose vaccines developed by Pfizer Inc. and German partner BioNTech SE and Moderna Inc. , or one shot of the Johnson & Johnson single-shot vaccine. --Pete Catapano
6:22 p.m. June 14, 2021 - By Jason Douglas
U.K. data show COVID-19 vaccines provide significant protection from delta variantSeparate studies from researchers in England and Scotland published Monday found that while protection against infection was somewhat diminished against delta compared with more established variants, two doses of vaccine offered considerable protection against severe illness and hospitalization.
1:15 p.m. June 14, 2021 - By MarketWatch Automation
1:09 p.m. June 14, 2021 - By MarketWatch Automation
1:00 p.m. June 14, 2021 - By MarketWatch Automation
12:46 p.m. June 14, 2021 - By MarketWatch Automation
12:41 p.m. June 14, 2021 - By MarketWatch Automation
12:40 p.m. June 14, 2021 - By MarketWatch Automation
12:36 p.m. June 14, 2021 - By MarketWatch Automation
12:33 p.m. June 14, 2021 - By MarketWatch Automation
12:32 p.m. June 14, 2021 - By MarketWatch Automation
10:44 a.m. June 14, 2021 - By Ciara Linnane
U.K. to delay reopening as Delta variant accounts for 90% of cases and U.S. court upholds mandatory vaccinationThe global tally of confirmed cases of COVID-19 climbed above 176 million on Monday, and U.K. Prime Minister Boris Johnson delayed the full lifting of restrictions on movement amid a surge in new cases caused by the Delta variant.
2:12 a.m. June 14, 2021 - By Steve Goldstein
Novavax reports COVID-19 vaccine was 90% effective in Phase 3 studyNovavax reported that a Phase 3 study of its COVID-19 vaccine showed it was 90.4% effective overall. The 29,960-patient study also found that the vaccine provided 100% protection against moderate and severe disease. The company intends to file for regulatory authorizations in the third quarter, and it said it remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021. Shares in the Gaithersburg, Md. company jumped 8% in premarket trade.
5:57 a.m. June 12, 2021 - By Tomi Kilgore
New U.S. COVID-19 cases and deaths jump to two weeks highsThe number of new daily COVID-19 cases and deaths jumped to the highest levels in more than two weeks, as the daily vaccination rate continues to suggest President Biden's goal won't be met.
Browse topics:

Filter results by

Location

Us (415)

Europe (110)

Eu (74)

Asia Pacific (72)

China (48)

Uk (20)

Link to MarketWatch's Slice.